CN117396476A - 取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物 - Google Patents

取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物 Download PDF

Info

Publication number
CN117396476A
CN117396476A CN202280039035.9A CN202280039035A CN117396476A CN 117396476 A CN117396476 A CN 117396476A CN 202280039035 A CN202280039035 A CN 202280039035A CN 117396476 A CN117396476 A CN 117396476A
Authority
CN
China
Prior art keywords
alkyl
group
het
substituted
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039035.9A
Other languages
English (en)
Chinese (zh)
Inventor
蔡伟
J·W·J·图灵
F·胡尔皮亚
戴学东
厉铭
邓向君
梁超
A·T·F·吴
孙圳
章志高
S·D·德敏
N·N·杜班科娃
M·D·茹弗鲁瓦
S·勒普利
N·F·J·B·达维尔
V·潘德
W·B·G·舍彭斯
J·P·爱德华兹
O·A·G·克罗尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN117396476A publication Critical patent/CN117396476A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280039035.9A 2021-06-01 2022-05-30 取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物 Pending CN117396476A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021097679 2021-06-01
CNPCT/CN2021/097679 2021-06-01
CNPCT/CN2022/085680 2022-04-08
CN2022085680 2022-04-08
PCT/CN2022/095901 WO2022253167A1 (en) 2021-06-01 2022-05-30 SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CN117396476A true CN117396476A (zh) 2024-01-12

Family

ID=82016507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039035.9A Pending CN117396476A (zh) 2021-06-01 2022-05-30 取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物

Country Status (19)

Country Link
US (1) US20230250096A1 (https=)
EP (1) EP4347588A1 (https=)
JP (1) JP2024521879A (https=)
KR (1) KR20240016324A (https=)
CN (1) CN117396476A (https=)
AR (1) AR126011A1 (https=)
AU (1) AU2022286467A1 (https=)
CA (1) CA3218479A1 (https=)
CL (1) CL2023003531A1 (https=)
CO (1) CO2023016217A2 (https=)
CR (1) CR20230605A (https=)
DO (1) DOP2023000250A (https=)
EC (1) ECSP23095641A (https=)
IL (1) IL308862A (https=)
MX (1) MX2023014347A (https=)
PE (1) PE20242359A1 (https=)
TW (1) TW202313606A (https=)
UY (1) UY39795A (https=)
WO (1) WO2022253167A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
US20250197392A1 (en) 2022-04-08 2025-06-19 Janssen Pharmaceutica Nv Crystalline forms of an inhibitor of the menin/mll interaction
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
AR132185A1 (es) * 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
WO2025119184A1 (zh) * 2023-12-04 2025-06-12 首药控股(北京)股份有限公司 取代的多环化合物
WO2026062248A1 (en) * 2024-09-20 2026-03-26 Acerta Pharma B.V. Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
IN2014DN01883A (https=) 2011-09-14 2015-05-15 Proximagen Ltd
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) * 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
JP7618567B2 (ja) 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Also Published As

Publication number Publication date
DOP2023000250A (es) 2024-04-30
ECSP23095641A (es) 2024-01-31
AR126011A1 (es) 2023-08-30
PE20242359A1 (es) 2024-12-16
IL308862A (en) 2024-01-01
CO2023016217A2 (es) 2023-12-11
EP4347588A1 (en) 2024-04-10
TW202313606A (zh) 2023-04-01
CA3218479A1 (en) 2022-12-08
WO2022253167A1 (en) 2022-12-08
UY39795A (es) 2022-11-30
CL2023003531A1 (es) 2024-06-14
JP2024521879A (ja) 2024-06-04
MX2023014347A (es) 2023-12-13
AU2022286467A1 (en) 2024-01-25
US20230250096A1 (en) 2023-08-10
WO2022253167A8 (en) 2023-03-09
CR20230605A (es) 2024-05-24
KR20240016324A (ko) 2024-02-06

Similar Documents

Publication Publication Date Title
CN117396476A (zh) 取代的苯基-1H-吡咯并[2,3-c]吡啶衍生物
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
JP7553450B2 (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
AU2018243691B2 (en) Heterocyclic compound
EP2370407B1 (en) Carbazole and carboline kinase inhibitors
KR20200100632A (ko) Ｋｒａｓ ｇ12ｃ 억제제
KR20180135885A (ko) 브루톤 티로신 키나제 억제제
AU2022272692A1 (en) Substituted spiro derivatives
AU2022275192A1 (en) Substituted spiro derivatives
CN120769853A (zh) 用于靶向tp53-y220c突变体的化合物和组合物
KR20210108433A (ko) 티에노피리디논 화합물
WO2024114664A1 (en) Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
CN120435473A (zh) 取代的1-苯基-3,4-二氢吡啶并[3,4-d]嘧啶-2-酮衍生物
CN120282784A (zh) 包含多发性内分泌癌蛋白-mll抑制剂和bcl-2抑制剂的组合
CN120359221A (zh) 环丁基取代的双环化合物
CA3218340A1 (en) Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
HK40100105A (zh) 取代的苯基-1h-吡咯并[2，3-c]吡啶衍生物
AU2024284667A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
HK40105326A (zh) 取代的螺环衍生物
HK40013646A (en) Azepane inhibitors of menin-mll interaction
HK40008247A (en) Fused bicyclic inhibitors of menin-mll interaction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100105

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination